Several landmark trials, including the DAPA-HF and EMPEROR-Reduced, have underscored the efficacy of SGLT2 inhibitors in reducing HF hospitalizations and cardiovascular mortality (Goldman et al., 2023). This evidence concerns the gene SLC5A2 and hydrops fetalis.